Ensysce BiosciencesENSC +0.73%23 EV-to-OCF is -0.36 as of Jul. 09, 2026. GuruFocus rates ENSC with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Ensysce Biosciences ranks worse than 69.2% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Ensysce Biosciences's Enterprise Value is $3.43 Mil.
Ensysce Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-9.60 Mil. Therefore, Ensysce Biosciences's EV-to-OCF for today is -0.36.
The historical rank and industry rank for Ensysce Biosciences's EV-to-OCF or its related term are showing as below:
ENSC'
s EV-to-OCF Range Over the Past 10 Years
Min: -0.36 Med: 0 Max: -0.34
Current: -0.36
During the past 6 years, the highest EV-to-OCF of Ensysce Biosciences was -0.34. The lowest was -0.36. And the median was .
ENSC's EV-to-OCF is ranked worse than 69.2% of 1409
companies
in the Biotechnology industry
Industry Median: -3.51
vs ENSC: -0.36
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ensysce Biosciences's PE Ratio (TTM) for today is calculated as:
Ensysce Biosciences's share price for today is $0.277.
Ensysce Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.350.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ensysce Biosciences EV-to-OCF Related Terms
Ensysce Biosciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Ensysce Biosciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ensysce Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ensysce Biosciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Ensysce Biosciences's EV-to-OCF falls into.
Ensysce Biosciences's current Enterprise Value is $3.43 Mil.
Ensysce Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ensysce Biosciences (ENSC) has a EV-to-OCF of -0.36 as of Jul. 09, 2026. According to the industry distribution chart, Ensysce Biosciences ranks #975 out of 1409 companies in the Biotechnology industry, placing it in the top 69.2%.
Is Ensysce Biosciences' EV-to-OCF too high?
Ensysce Biosciences' current EV-to-OCF is -0.36. Based on the distribution chart, Ensysce Biosciences ranks #975 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ensysce Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Ensysce Biosciences' EV-to-OCF compare to RNAZ and ALZN?
According to the Biotechnology industry distribution chart, Ensysce Biosciences ranks #975 out of 1409 companies for EV-to-OCF. This places Ensysce Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Ensysce Biosciences's current EV-to-OCF is -0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ensysce Biosciences stock overvalued right now?
Ensysce Biosciences (ENSC) has a current EV-to-OCF of -0.36. The current EV-to-OCF is -0.36. Ensysce Biosciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Ensysce Biosciences (ENSC), the current EV-to-OCF is -0.36 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
23GF Score
Get the complete analysis for ENSC
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENSC has been successfully added to your 
